Table 4.
Overall Mortality Among Patients With Pancreatic Cancer by Pre-diagnosis Statin Use Stratified by Covariates.
| Pre-diagnosis statin use
|
|||||
|---|---|---|---|---|---|
| No. of | No. of | Non-regular use | Regular use | ||
| Covariate | cases | deaths | HR | HR (95% CI)a | Pinteraction |
| Year of diagnosis | .64 | ||||
| 2000–2005 | 283 | 280 | 1 (referent) | 0.86 (0.66–1.11) | |
| 2006–2013 | 365 | 353 | 1 (referent) | 0.79 (0.64–0.98) | |
| Smoking status | .89 | ||||
| Never | 273 | 265 | 1 (referent) | 0.80 (0.62–1.04) | |
| Past | 325 | 319 | 1 (referent) | 0.86 (0.68–1.08) | |
| Current | 44 | 44 | 1 (referent) | 0.76 (0.41–1.39) | |
| Body mass index | .79 | ||||
| < 25 kg/m2 | 305 | 297 | 1 (referent) | 0.85 (0.66–1.10) | |
| ≥ 25 kg/m2 | 343 | 336 | 1 (referent) | 0.81 (0.65–1.01) | |
| Diabetes status | .98 | ||||
| No diabetes | 501 | 489 | 1 (referent) | 0.83 (0.68–1.00) | |
| Recent-onset (≤ 4 years) | 31 | 30 | 1 (referent) | 0.83 (0.41–1.71) | |
| Long-standing (> 4 years) | 116 | 114 | 1 (referent) | 0.80 (0.54–1.17) | |
| Cancer stage | .54 | ||||
| Localized | 91 | 83 | 1 (referent) | 1.11 (0.71–1.74) | |
| Locally advanced | 46 | 43 | 1 (referent) | 0.93 (0.50–1.75) | |
| Metastatic | 328 | 327 | 1 (referent) | 0.84 (0.66–1.07) | |
HR, hazard ratio.
a
The Cox proportional hazards model was adjusted for the following covariates except for the stratification variable: age at diagnosis (continuous), cohort (sex), race/ethnicity (white, black, other, or unknown), year of diagnosis (2000–2005 or 2006–2013), smoking status (never, past, current, or unknown), body mass index (continuous), and diabetes status (no, recent-onset, or long-standing).